Avril is a consultant/advisory board member for steering committee for trial MO25743: Vemurafenib in Brain Metastasis of Melanoma Patients ,
Caignard Development of methodology: A. Frazao Avril Acquisition of data (provided animals, acquired and managed patients, provided facilities Avril Analysis and interpretation of data (e.g., statistical analysis, biostatistics, computational analysis): A Avril Writing, review, and/or revision of the manuscript, technical, or material support (i.e., reporting or organizing data, constructing databases): H. Benlalam Study supervision: A. Caignard Other, pp.949-54, 2002. ,
Challenging resistance mechanisms to therapies for metastatic melanoma, Trends in Pharmacological Sciences, vol.34, issue.12, pp.656-66, 2013. ,
DOI : 10.1016/j.tips.2013.10.003
Tumor adaptation and resistance to RAF inhibitors, Nature Medicine, vol.31, issue.11, pp.1401-1410, 2013. ,
DOI : 10.1038/nature11814
Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation, New England Journal of Medicine, vol.364, issue.26, pp.2507-2523, 2011. ,
DOI : 10.1056/NEJMoa1103782
Phenotypic and Functional Characteristics of Blood Natural Killer Cells from Melanoma Patients at Different Clinical Stages, PLoS ONE, vol.363, issue.10, p.76928, 2013. ,
DOI : 10.1371/journal.pone.0076928.s003
URL : https://hal.archives-ouvertes.fr/hal-01619167
Unique Functional Status of Natural Killer Cells in Metastatic Stage IV Melanoma Patients and Its Modulation by Chemotherapy, Clinical Cancer Research, vol.17, issue.9, pp.2628-2665, 2011. ,
DOI : 10.1158/1078-0432.CCR-10-2084
Natural Killer Cells Activated by MHC Class ILow Targets Prime Dendritic Cells to Induce Protective CD8 T Cell Responses, Immunity, vol.19, issue.4, pp.561-570, 2003. ,
DOI : 10.1016/S1074-7613(03)00264-4
URL : https://doi.org/10.1016/s1074-7613(03)00264-4
Unravelling natural killer cell function: triggering and inhibitory human NK receptors, The EMBO Journal, vol.23, issue.2, pp.255-264, 2004. ,
DOI : 10.1038/sj.emboj.7600019
URL : http://emboj.embopress.org/content/embojnl/23/2/255.full.pdf
Activation, coactivation, and costimulation of resting human natural killer cells, Immunological Reviews, vol.137, issue.1, pp.73-91, 2006. ,
DOI : 10.1158/0008-5472.CAN-05-4603
URL : https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3845883/pdf
NCRs and DNAM-1 mediate NK cell recognition and lysis of human and mouse melanoma cell lines in vitro and in vivo, Journal of Clinical Investigation, vol.119, issue.5, pp.1251-63, 2009. ,
DOI : 10.1172/JCI36022DS1
The CD94/ NKG2 C-type lectin receptor complex, Curr Top Microbiol Immunol, vol.230, pp.41-52, 1998. ,
Natural killer cells in the host response to melanoma, Cancer Res, vol.47, pp.1411-1413, 1987. ,
Cytotoxic Markers and Frequency Predict Functional Capacity of Natural Killer Cells Infiltrating Renal Cell Carcinoma, Clinical Cancer Research, vol.12, issue.3, pp.718-743, 2006. ,
DOI : 10.1158/1078-0432.CCR-05-0857
URL : http://clincancerres.aacrjournals.org/content/clincanres/12/3/718.full.pdf
Expression of stress ligands of the immunoreceptor NKG2D in melanoma: Regulation and clinical significance, European Journal of Cell Biology, vol.93, issue.1-2, pp.49-54, 2014. ,
DOI : 10.1016/j.ejcb.2014.01.009
Role of Altered Expression of HLA Class I Molecules in Cancer Progression ,
DOI : 10.1007/978-0-387-72005-0_13
Serum Soluble HLA-E in Melanoma: A New Potential Immune-Related Marker in Cancer, PLoS ONE, vol.87, issue.1, p.21118, 2011. ,
DOI : 10.1371/journal.pone.0021118.t002
URL : https://hal.archives-ouvertes.fr/inserm-01234644
Expression and Release of HLA-E by Melanoma Cells and Melanocytes: Potential Impact on the Response of Cytotoxic Effector Cells, The Journal of Immunology, vol.177, issue.5, pp.3100-3107, 2006. ,
DOI : 10.4049/jimmunol.177.5.3100
A melanoma immune response signature including Human Leukocyte Antigen-E, Pigment Cell & Melanoma Research, vol.469, issue.1, pp.103-115, 2014. ,
DOI : 10.1038/nature09666
Inhibition of the NKp30 activating receptor by pp65 of human cytomegalovirus, Nature Immunology, vol.70, issue.5, pp.515-538, 2005. ,
DOI : 10.1021/bi020117v
Dendritic Cells Release HLA-B-Associated Transcript-3 Positive Exosomes to Regulate Natural Killer Function, PLoS ONE, vol.26, issue.10, p.3377, 2008. ,
DOI : 10.1371/journal.pone.0003377.g004
URL : https://doi.org/10.1371/journal.pone.0003377
The B7 family member B7-H6 is a tumor cell ligand for the activating natural killer cell receptor NKp30 in humans, The Journal of Experimental Medicine, vol.163, issue.7, pp.1495-503, 2009. ,
DOI : 10.1038/nri2326
B7-H6/NKp30 interaction: a mechanism of alerting NK cells against tumors, Cellular and Molecular Life Sciences, vol.282, issue.Suppl 9, pp.3531-3540, 2011. ,
DOI : 10.1074/jbc.M702504200
URL : https://hal.archives-ouvertes.fr/hal-00667776
Tumor Therapeutics Work as Stress Inducers to Enhance Tumor Sensitivity to Natural Killer (NK) Cell Cytolysis by Up-regulating NKp30 Ligand B7-H6, Journal of Biological Chemistry, vol.22, issue.50, pp.29964-73, 2015. ,
DOI : 10.1182/blood-2013-02-482513
URL : http://www.jbc.org/content/290/50/29964.full.pdf
Vemurafenib Potently Induces Endoplasmic Reticulum Stress-Mediated Apoptosis in BRAFV600E Melanoma Cells, Science Signaling, vol.6, issue.8, p.7, 2013. ,
DOI : 10.1371/journal.pone.0023429
URL : https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3698985/pdf
Immunological Visibility: Posttranscriptional Regulation of Human NKG2D Ligands by the EGF Receptor Pathway, Science Translational Medicine, vol.8, issue.1, pp.231-280, 2014. ,
DOI : 10.1093/biostatistics/kxj037
Valproic Acid Upregulates NKG2D Ligand Expression through an ERK-dependent Mechanism and Potentially Enhances NK Cell-mediated Lysis of Myeloma, Neoplasia, vol.14, issue.12, pp.1178-89, 2012. ,
DOI : 10.1593/neo.121236
NKG2D ligands are expressed on stressed human airway epithelial cells, AJP: Lung Cellular and Molecular Physiology, vol.291, issue.2, pp.222-253, 2006. ,
DOI : 10.1152/ajplung.00327.2005
URL : http://ajplung.physiology.org/content/ajplung/291/2/L222.full.pdf
Resistance to Cytarabine Induces the Up-regulation of NKG2D Ligands and Enhances Natural Killer Cell Lysis of Leukemic Cells, Neoplasia, vol.10, issue.12, pp.1402-1412, 2008. ,
DOI : 10.1593/neo.08972
NKG2D- and T-cell receptor-dependent lysis of malignant glioma cell lines by human ???? T cells: Modulation by temozolomide and A disintegrin and metalloproteases 10 and 17 inhibitors, OncoImmunology, vol.146, issue.4, p.1093276, 2016. ,
DOI : 10.1128/CDLI.8.6.1131???1135.2001
Metalloprotease-Mediated Tumor Cell Shedding of B7-H6, the Ligand of the Natural Killer Cell-Activating Receptor NKp30, Cancer Research, vol.74, issue.13, pp.3429-3469, 2014. ,
DOI : 10.1158/0008-5472.CAN-13-3017
Extracellular Signal-regulated Kinase Phosphorylates Tumor Necrosis Factor ??-converting Enzyme at Threonine 735: A Potential Role in Regulated Shedding, Molecular Biology of the Cell, vol.269, issue.6, pp.2031-2075, 2002. ,
DOI : 10.1074/jbc.271.31.18989
ERK-mediated phosphorylation of Thr735 in TNF??-converting enzyme and its potential role in TACE protein trafficking, Journal of Cell Science, vol.118, issue.11, pp.2371-80, 2005. ,
DOI : 10.1242/jcs.02357
homozygous melanoma cells, OncoImmunology, vol.48, issue.1, p.22890, 2013. ,
DOI : 10.1158/1535-7163.MCT-06-0728
HLA class I downregulation is associated with enhanced NK-cell killing of melanoma cells with acquired drug resistance to BRAF inhibitors, European Journal of Immunology, vol.80, issue.2, pp.409-428, 2016. ,
DOI : 10.1002/(SICI)1097-0215(19990301)80:5<781::AID-IJC24>3.0.CO;2-A
Effects of anti-NKG2A antibody administration on leukemia and normal hematopoietic cells, Haematologica, vol.101, issue.5, pp.626-659, 2016. ,
DOI : 10.3324/haematol.2015.135301
Preclinical characterization of 1-7F9, a novel human anti-KIR receptor therapeutic antibody that augments natural killer-mediated killing of tumor cells, Blood, vol.114, issue.13, pp.2667-77, 2009. ,
DOI : 10.1182/blood-2009-02-206532
URL : https://hal.archives-ouvertes.fr/hal-00431858
The Oncogenic BRAF Kinase Inhibitor PLX4032/RG7204 Does Not Affect the Viability or Function of Human Lymphocytes across a Wide Range of Concentrations, Clinical Cancer Research, vol.16, issue.24, pp.6040-6048, 2010. ,
DOI : 10.1158/1078-0432.CCR-10-1911
Differential influence of vemurafenib and dabrafenib on patients??? lymphocytes despite similar clinical efficacy in melanoma, Annals of Oncology, vol.25, issue.3, pp.747-53, 2014. ,
DOI : 10.1093/annonc/mdt587
DNAM-1 control of natural killer cells functions through nectin and nectin-like proteins, Immunology and Cell Biology, vol.172, issue.3, pp.237-281, 2014. ,
DOI : 10.1056/NEJMoa1104621
Combination therapy with BRAF and MEK inhibitors for melanoma: latest evidence and place in therapy, Therapeutic Advances in Medical Oncology, vol.33, issue.1, pp.48-56, 2016. ,
DOI : 10.1158/1078-0432.CCR-11-2479
Cytokines can counteract the inhibitory effect of MEK-i on NK-cell function, Oncotarget, vol.7, issue.38, pp.60858-71, 2016. ,
DOI : 10.18632/oncotarget.11504
Cancerinduced alterations of NK-mediated target recognition: current and investigational pharmacological strategies aiming at restoring NK-mediated anti-tumor activity, Front Immunol, vol.5, p.122, 2014. ,
Selective BRAFV600E Inhibition Enhances T-Cell Recognition of Melanoma without Affecting Lymphocyte Function, Cancer Research, vol.70, issue.13, pp.5213-5222, 2010. ,
DOI : 10.1158/0008-5472.CAN-10-0118
URL : http://cancerres.aacrjournals.org/content/canres/70/13/5213.full.pdf
Natural Killer Cells Are Essential for the Ability of BRAF Inhibitors to Control BRAFV600E-Mutant Metastatic Melanoma, Cancer Research, vol.74, issue.24, pp.7298-308, 2014. ,
DOI : 10.1158/0008-5472.CAN-14-1339
MAP Kinase Inhibition Promotes T Cell and Anti-tumor Activity in Combination with PD-L1 Checkpoint Blockade, Immunity, vol.44, issue.3, pp.609-630, 2016. ,
DOI : 10.1016/j.immuni.2016.01.024
URL : https://doi.org/10.1016/j.immuni.2016.01.024
Selective BRAF inhibition decreases tumor-resident lymphocyte frequencies in a mouse model of human melanoma, OncoImmunology, vol.1, issue.5, pp.609-626, 2012. ,
DOI : 10.1002/cncr.25747
Targeting the tumor microenvironment to improve natural killer cell-based immunotherapies: On being in the right place at the right time, with resilience, Human Vaccines & Immunotherapeutics, vol.9, issue.3, pp.607-618, 2016. ,
DOI : 10.1016/j.intimp.2013.06.003
Therapeutic potential and challenges of natural killer cells in treatment of solid tumors, Front Immunol, vol.29, pp.202-209, 2015. ,